Quarterly ResultApr 28, 2026, 04:06 PM
OPK Initiates 2 Phase 1 Trials; Expands Entera Bio Partnership
AI Summary
OPKO Health reported Q1 2026 financial results, with consolidated total revenues of $124.2 million, down from $149.9 million YoY, primarily due to asset sales. However, the company significantly improved its operating loss to $51.0 million from $67.2 million and net loss to $54.8 million from $67.6 million. Operationally, OPKO initiated Phase 1 clinical trials for MDX2301 (COVID-19 prevention) and MDX2003 (B-cell lymphoma) and expanded its partnership with Entera Bio to advance an oral long-acting PTH tablet, with an IND filing expected in late 2026. The company also provided Q2 and full-year 2026 financial guidance.
Key Highlights
- Initiated MDX2301 Phase 1 clinical trial for COVID-19 prevention.
- Initiated MDX2003 Phase 1 clinical trial for B-cell lymphoma.
- Expanded partnership with Entera Bio for oral PTH, targeting late 2026 IND filing.
- Q1 2026 consolidated total revenues $124.2M, down from $149.9M YoY.
- Q1 2026 consolidated net loss improved to $54.8M ($0.07/share) from $67.6M ($0.10/share) YoY.
- Pharmaceutical product revenue increased to $38.0M from $34.8M YoY.
- Cash, cash equivalents, marketable securities, and restricted cash were $341.9M.
- Q2 2026 total revenue guidance $127M-$132M.